Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 8Lymphoma, Large-Cell, Anaplastic 4Carcinoma 3Brain Neoplasms 2ALK-positive Advanced NSCLC 2Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Meningioma 1Granuloma, Plasma Cell 1Gastrointestinal Neoplasms 1Ependymoma 1Disease Progression 1Carcinoma, Squamous Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Large Cell 1Breast Neoplasms 1Adenocarcinoma 1ALK+ Advanced NSCLC 1

Interventions

Gemcitabine 15130-nm albumin-bound paclitaxel 10Albumin-Bound Paclitaxel 7Oxaliplatin 5Paclitaxel 4Leucovorin 4Fluorouracil 4Carboplatin 4Cisplatin 3Cetuximab 3Bevacizumab 3pembrolizumab 2napabucasin 2Pemetrexed 2PEGPH20 2MK-4721 2Irinotecan 2tremelimumab 1selinexor 1relacorilant 1ponatinib 1neratinib 1irinotecan sucrosofate 1folfirinox 1ensituximab 1durvalumab 1contrast agent BR1 1cobimetinib 1ceritinib 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Pancreatic Ductal × brigatinib × Clear all
NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

University Health Network, Toronto

Phase 2 Not yet recruiting
25 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡